Ranibizumab biosimilar (Celon pharma)

雷珠单抗生物类似药 (Celon pharma)

Report date: 2024/05/15 17:55:19

Base Information

Drug NameRanibizumab biosimilar (Celon pharma)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsDiabetic macular oedemaRetinal Vein OcclusionMacular Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCelon Pharma Sa

China Registration ClassN/A

Develop Information

Active CompaniesCelon Pharma Sa

Inactive CompaniesN/A

Active IndicationsDiabetic macular oedemaRetinal Vein OcclusionMacular Degeneration

Inactive IndicationsN/A

Other Information

ATC CodeN/A